Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute

Dr. Paul Richardson, shares three platforms for today's therapies: targeting the tumor environment, leveraging the immune system, and

Posted by

HealthTree

A compelling European approach in myeloma care: Collaboration, Referrals and Established Guidelines with Dr. Pieter Sonneveld, MD, PhD, Erasmus MC

With smaller individual myeloma patient populations, the Europeans had to develop a different strategy in order to make progress in myeloma treatment.

Posted by

HealthTree

Race and obesity in multiple myeloma with Dr. Vincent Rajkumar, MD, Mayo Clinic

Dr. Rajkumar describes findings on the two to three times increase in myeloma in blacks over whites and his observations that obesity provides a risk factor

Posted by

HealthTree

Myeloma is not a single disease: The illuminating discovery and implications for care with Dr. Michael Kuehl, MD, PhD of the NCI

Dr. Kuehl, in partnership with Dr. Bergsagel, discovered that myeloma is not a single disease

Posted by

HealthTree

Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants

Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants

Posted by

HealthTree

Dr. Jonathan Licht, MD on high-risk 4;14 myeloma and MMSET's function and future targets

Dr. Shapira shares work done to test a myeloma vaccine from Vaxil called ImMucin that targets the MUC1 oncoprotein

Posted by

HealthTree

Dr. Aaron Rapoport, MD on the progress and potential for T-cell and vaccine myeloma therapies

Dr. Aaron Rapoport shares the progress being made on T cell and vaccine immunotherapy.

Posted by

HealthTree